Shopping Cart 0
Cart Subtotal
USD 0

University of Minnesota - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

University of Minnesota (UM) is an educational institute that offers research, education and outreach services. The institute offers educational programs in the areas of medicine, social sciences, science and business. It offers under graduate degree, post graduate, masters and research courses. UM's schools and colleges offers courses in the areas of allied health programs, biological sciences, continuing education, dentistry, design, education and human development, extension, food, and agricultural and natural resource sciences. The institute offers graduate and professional programs in the areas of accountancy, aerospace engineering, animal sciences, applied plant sciences, biomedical engineering, chemical engineering, economics, food science, geography, and others . UM is headquartered in Minneapolis, Minnesota, the US.

University of Minnesota-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

University of Minnesota, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

University of Minnesota, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

University of Minnesota, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

University of Minnesota, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

University of Minnesota, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

University of Minnesota, Pharmaceuticals & Healthcare, Deal Details 12

Partnerships 12

Context Therapeutics Enters into Research Collaborations for Apristor 12

Magenta Therapeutics Enters into Agreement with University of Minnesota 14

Oxis International Enters into Research Agreement with University of Minnesota 15

Oxis International Enters into Research Agreement with University of Minnesota 16

Biocept Enters into Research Agreement with University of Minnesota 17

Five Prime Therapeutics Enters into Agreement with University of Minnesota Medical School 18

Hennepin County Medical Center, University of Minnesota and Abbott Labs Enter into Agreement 19

Targazyme Enters into Agreement with University of Minnesota Medical Center 20

Fate Therapeutics Enters into Research Agreement with Regents of the University of Minnesota 21

Licensing Agreements 22

Oxis Biotech Enters into Licensing Agreement with University of Minnesota 22

Amal Therapeutics Enters into Patent Licensing Agreement with University of Minnesota 23

PlasmaTech Biopharma Enters into Licensing Agreement with University of Minnesota 24

Apogen Biotech Enters into Licensing Agreement with University of Minnesota 25

Regenxbio Enters into Licensing Agreement with University of Pennsylvania and University of Minnesota 26

Arno Therapeutics Enters Into Licensing Agreement With University of Minnesota 27

RedHill Biopharma Enters into Licensing Agreement with University of Minnesota 28

Minneamrita Therapeutics Enters into Licensing Agreement with University of Minnesota 29

University Of Minnesota Enters Into Licensing Agreement With Vytacera Pharma 30

University of Minnesota-Key Competitors 31

University of Minnesota-Key Employees 32

University of Minnesota-Locations And Subsidiaries 33

Head Office 33

Other Locations & Subsidiaries 33

Recent Developments 35

Government and Public Interest 35

Sep 24, 2018: FDA awards 12 grants to fund new clinical trials to advance the development of medical products for the treatment of rare diseases 35

Aug 16, 2018: CoreBiome awarded Technology Commercialization Grant 37

Aug 02, 2018: UMD-Led team receives USD 7.7 Million NIH grant for first-of-its-kind tick-borne disease research 38

Jul 24, 2018: Changes in bacterial mix linked to antibiotics increase risk for type 1 diabetes in animal model 39

Jul 18, 2018: St. Baldrick's foundation announces USD 19.1 million in grants to fund lifesaving childhood cancer research 41

Apr 02, 2018: UMN Medical School Study Explores Upstream Factors for Atrial Fibrillation-Related Stroke and Dementia 42

Feb 14, 2018: Rein in Sarcoma Foundation Announces 2018 Research Grants 43

Nov 14, 2017: St. Baldrick's Foundation Announces USD 2.2 Million in Grants to Give More Kids Access to Clinical Trials 44

Nov 09, 2017: New Researcher at The Hormel Institute Awarded Ovarian Cancer Research Grant 45

Oct 24, 2017: Identifying the mechanism for a new class of antiviral drugs could hasten their approval 46

May 09, 2017: Delta-Opioid Agonists Can Attenuate Cardiac Injury 47

Product News 48

Jun 19, 2018: Researchers develop a better method to compare gene expression in single cells 48

Apr 11, 2018: Research Brief: Vaccines to treat opioid abuse and prevent fatal overdoses 50

Other Significant Developments 51

Apr 09, 2018: U of M launches cancer clinical trials network, partnering with clinics across MN 51

Appendix 52

Methodology 52

About GlobalData 52

Contact Us 52

Disclaimer 52


List Of Figure

List of Figures

University of Minnesota, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

University of Minnesota, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

University of Minnesota, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

University of Minnesota, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

University of Minnesota, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

University of Minnesota, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

University of Minnesota, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

University of Minnesota, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

University of Minnesota, Pharmaceuticals & Healthcare, Key Facts 2

University of Minnesota, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

University of Minnesota, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

University of Minnesota, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

University of Minnesota, Deals By Therapy Area, 2012 to YTD 2018 9

University of Minnesota, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Context Therapeutics Enters into Research Collaborations for Apristor 12

Magenta Therapeutics Enters into Agreement with University of Minnesota 14

Oxis International Enters into Research Agreement with University of Minnesota 15

Oxis International Enters into Research Agreement with University of Minnesota 16

Biocept Enters into Research Agreement with University of Minnesota 17

Five Prime Therapeutics Enters into Agreement with University of Minnesota Medical School 18

Hennepin County Medical Center, University of Minnesota and Abbott Labs Enter into Agreement 19

Targazyme Enters into Agreement with University of Minnesota Medical Center 20

Fate Therapeutics Enters into Research Agreement with Regents of the University of Minnesota 21

Oxis Biotech Enters into Licensing Agreement with University of Minnesota 22

Amal Therapeutics Enters into Patent Licensing Agreement with University of Minnesota 23

PlasmaTech Biopharma Enters into Licensing Agreement with University of Minnesota 24

Apogen Biotech Enters into Licensing Agreement with University of Minnesota 25

Regenxbio Enters into Licensing Agreement with University of Pennsylvania and University of Minnesota 26

Arno Therapeutics Enters Into Licensing Agreement With University of Minnesota 27

RedHill Biopharma Enters into Licensing Agreement with University of Minnesota 28

Minneamrita Therapeutics Enters into Licensing Agreement with University of Minnesota 29

University Of Minnesota Enters Into Licensing Agreement With Vytacera Pharma 30

University of Minnesota, Key Competitors 31

University of Minnesota, Key Employees 32

University of Minnesota, Subsidiaries 33

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

University of Minnesota, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.